Related Experiment Videos
Safety of rosuvastatin
James Shepherd1, Donald B Hunninghake, Evan A Stein
1Department of Vascular Biochemistry, University of Glasgow, Glasgow, Scotland. jshepherd@gri-biochem.org.uk <jshepherd@gri-biochem.org.uk>
The American Journal of Cardiology
|October 7, 2004
Summary
Rosuvastatin demonstrated a favorable safety profile in a large clinical program, with adverse events comparable to placebo and other statins. This cholesterol-lowering drug was well-tolerated, showing low rates of muscle-related issues and no treatment-related deaths.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Clinical Trials
Background:
- Dyslipidemia is a major risk factor for cardiovascular disease.
- Statins are widely prescribed to manage cholesterol levels.
- Assessing the safety and tolerability of new statin medications is crucial.
Purpose of the Study:
- To evaluate the safety and tolerability of rosuvastatin.
- To compare rosuvastatin's adverse event profile with placebo and other statins.
- To analyze laboratory data and clinical outcomes in a large patient population.
Main Methods:
- Integrated safety data from a multinational phase II/III clinical program.
- Inclusion of 12,400 patients with 12,212 patient-years of rosuvastatin exposure.
- Analysis of adverse events, laboratory abnormalities, and clinical events.
Main Results:
- Adverse event rates for rosuvastatin were similar to placebo.
- Rosuvastatin showed a comparable safety profile to atorvastatin, simvastatin, and pravastatin.
- Clinically significant liver enzyme elevations and myopathy were rare (<0.2% and <0.03% respectively).
- Proteinuria findings were comparable to other statins and not predictive of renal disease.
- No deaths or rhabdomyolysis were attributed to rosuvastatin treatment.
Conclusions:
- Rosuvastatin is well-tolerated in patients with dyslipidemia.
- The safety profile of rosuvastatin is similar to that of comparator statins.
- Rosuvastatin represents a safe treatment option for managing cholesterol.